-
公开(公告)号：US10472682B2
公开(公告)日：2019-11-12
申请号：US14869563
申请日：2015-09-29
Applicant: Samsung Electronics Co., Ltd.
Inventor： Seon Hui Shim , Soo Yeon Jung , Kyung Ah Kim
IPC: C12Q1/6886 , C07K16/30 , C07K16/28 , A61K39/00
Abstract: A method for predicting and/or monitoring the efficacy of a c-Met inhibitor using a biomarker; a method for selecting a subject suitable for the application of a c-Met inhibitor using a biomarker; and a method for preventing and/or treating cancer comprising administering a c-Met inhibitor to the selected subject.
-
12.发明授权Method of combination therapy using an EGFR antagonist and anti-c-Met antibody 有权使用EGFR拮抗剂和抗c-Met抗体的联合治疗方法公开(公告)号：US09572878B2
公开(公告)日：2017-02-21
申请号：US14227759
申请日：2014-03-27
Inventor： Saet Byoul Lee , Jae Hyun Choi , Kyung Ah Kim , Ji Min Lee , Yun Ju Jeong , Keunchil Park , Youngwook Kim , Yumi Lee
IPC: A61K39/395 , A61K31/517 , A61K31/5377
CPC classification number: A61K39/3955 , A61K31/517 , A61K31/5377 , A61K31/00 , A61K2300/00
Abstract: A method of combination therapy for prevention and/or treatment of c-Met- and/or EGFR-induced diseases including co-administering a pharmaceutically effective amount of an EGFR antagonist and a pharmaceutically effective amount of an anti-c-Met antibody to a subject in need thereof is provided.
Abstract translation: 用于预防和/或治疗c-Met-和/或EGFR诱导的疾病的组合疗法的方法，包括将药学有效量的EGFR拮抗剂和药学上有效量的抗c-Met抗体共同施用于 提供了有需要的受试者。
-
13.发明授权公开(公告)号：US09457081B2
公开(公告)日：2016-10-04
申请号：US14480174
申请日：2014-09-08
Applicant: Samsung Electronics Co., Ltd.
Inventor： Ji Min Lee , Kyung Ah Kim
IPC: A01N61/00 , A61K39/395 , A61K31/519 , A61K31/506 , A61K31/454 , C12N15/113 , C07K16/28 , A61K39/00
CPC classification number: A61K39/39558 , A61K31/454 , A61K31/4545 , A61K31/506 , A61K31/519 , A61K45/06 , A61K2039/505 , C07K16/2863 , C07K2317/24 , C07K2317/622 , C07K2317/73 , C07K2317/74 , C12N15/113 , C12N2310/14 , C12N2320/31 , A61K2300/00
Abstract: A method of preventing and/or treating a cancer including co-administering a c-Met inhibitor and a beta-catenin inhibitor to a subject in need thereof, a pharmaceutical composition comprising a c-Met inhibitor and a beta-catenin inhibitor, and a kit comprising a pharmaceutical composition comprising a c-Met inhibitor, and a pharmaceutical composition comprising a beta-catenin inhibitor packaged together.
Abstract translation: 一种预防和/或治疗癌症的方法，包括将c-Met抑制剂和β-连环蛋白抑制剂共同施用于有需要的受试者，包含c-Met抑制剂和β-连环蛋白抑制剂的药物组合物和 包含包含c-Met抑制剂的药物组合物的试剂盒和包含在一起包装的β-连环蛋白抑制剂的药物组合物。
-
公开(公告)号：US09457043B2
公开(公告)日：2016-10-04
申请号：US14481509
申请日：2014-09-09
Applicant: Samsung Electronics Co., Ltd.
Inventor： Ji Min Lee , Kyung Ah Kim
IPC: A61K39/395 , A61K31/7088 , C07K16/28 , A61K39/00
CPC classification number: A61K31/7088 , A61K31/713 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/2863 , C07K2317/24 , A61K2300/00
Abstract: A method of preventing and/or treating a cancer including co-administering a c-Met inhibitor and a c-Myc Inhibitor to a subject in need thereof, a pharmaceutical composition comprising a c-Met inhibitor and a c-Myc inhibitor, and a kit comprising a pharmaceutically effective amount of a c-Met inhibitor as an active ingredient, and a second pharmaceutical composition comprising a pharmaceutically effective amount of a c-Myc inhibitor as an active ingredient, packaged together.
Abstract translation: 一种预防和/或治疗癌症的方法，包括向有需要的受试者共同施用c-Met抑制剂和c-Myc抑制剂，包含c-Met抑制剂和c-Myc抑制剂的药物组合物和 试剂盒包含药学上有效量的c-Met抑制剂作为活性成分，以及包含药学有效量的作为活性成分的c-Myc抑制剂的第二药物组合物，包装在一起。
-
15.发明申请PDGF AS A BIOMARKER FOR PREDICTING RESISTANCE OR EFFECT OF C-MET TARGETING DRUGS 有权PDGF作为预测C-MET靶向药物的电阻或效应的生物标志物公开(公告)号：US20160061815A1
公开(公告)日：2016-03-03
申请号：US14836596
申请日：2015-08-26
Inventor： Jae Hyun Choi , Kyung Ah Kim , Youngwook Kim , Keunchil Park
IPC: G01N33/50
CPC classification number: G01N33/5011 , G01N2333/49 , G01N2800/52
Abstract: Provided is a method for evaluating efficacy of, or resistance to, a c-Met targeting agent including measuring a level of a PDGF protein and/or a PDGF coding gene.
Abstract translation: 提供了评估c-Met靶向剂的功效或抗性的方法，包括测量PDGF蛋白和/或PDGF编码基因的水平。
-
Patent Agency Ranking
16.发明授权Use of LRIG1 as a biomarker for identifying a subject for application of anti-c-Met antibodies 有权使用LRIG1作为鉴定受试者应用抗c-Met抗体的生物标志物公开(公告)号：US09213032B2
公开(公告)日：2015-12-15
申请号：US13949041
申请日：2013-07-23
Applicant: SAMSUNG ELECTRONICS CO., LTD.
Inventor： Ji Min Lee , Kyung Ah Kim , Bo Gyou Kim
CPC classification number: G01N33/57492 , A61K2039/505 , C07K16/2863 , C07K16/30 , C07K2317/24 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , G01N33/57496 , G01N2800/52
Abstract: A method of identifying a cell sample or subject suitable for treatment with an anti-c-Met antibody or antigen-binding fragment thereof that specifically binds to an epitope within a SEMA domain of a c-Met protein by determining the presence of LRIG1 in a cell sample from the subject, as well as related methods and compositions.
Abstract translation: 一种鉴定适合用抗c-Met抗体或其抗原结合片段治疗的细胞样品或受试者的方法，所述抗c-Met抗体或其抗原结合片段特异性结合c-Met蛋白质的SEMA结构域中的表位，通过确定c-Met蛋白中存在LRIG1 来自受试者的细胞样品，以及相关方法和组合物。
-
公开(公告)号：US20150212077A1
公开(公告)日：2015-07-30
申请号：US14604361
申请日：2015-01-23
Applicant: Samsung Electronics Co., Ltd.
Inventor： Bo Gyou Kim , Eunjin Lee , Kyung Ah Kim , Tae Jin Ahn
CPC classification number: C12Q1/6876 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/2863 , C07K16/3023 , C07K16/3046 , C07K2317/24 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2319/30 , C07K2319/32 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N33/574 , G01N2333/47 , G01N2800/52 , A61K2300/00
Abstract: A method of predicting an effect of a c-Met inhibitor and/or selecting a subject for application of a c-Met inhibitor using TFF1, a method of monitoring an effect of a c-Met inhibitor using TFF1, and a method of treating and/or preventing cancer including administering a c-Met inhibitor to the selected subject.
Abstract translation: 使用TFF1预测c-Met抑制剂的效果和/或选择使用c-Met抑制剂的受试者的方法，使用TFF1监测c-Met抑制剂的作用的方法，以及治疗和/ 包括给所选受试者施用c-Met抑制剂。
-
18.发明申请公开(公告)号：US20150071930A1
公开(公告)日：2015-03-12
申请号：US14480174
申请日：2014-09-08
Applicant: Samsung Electronics Co., Ltd.
Inventor： Ji Min Lee , Kyung Ah Kim
IPC: C07K16/32 , A61K31/519 , A61K39/395 , A61K31/454 , C12N15/113 , C07K16/18 , A61K31/506
CPC classification number: A61K39/39558 , A61K31/454 , A61K31/4545 , A61K31/506 , A61K31/519 , A61K45/06 , A61K2039/505 , C07K16/2863 , C07K2317/24 , C07K2317/622 , C07K2317/73 , C07K2317/74 , C12N15/113 , C12N2310/14 , C12N2320/31 , A61K2300/00
Abstract: A method of preventing and/or treating a cancer including co-administering a c-Met inhibitor and a beta-catenin inhibitor to a subject in need thereof, a pharmaceutical composition comprising a c-Met inhibitor and a beta-catenin inhibitor, and a kit comprising a pharmaceutical composition comprising a c-Met inhibitor, and a pharmaceutical composition comprising a beta-catenin inhibitor packaged together.
Abstract translation: 一种预防和/或治疗癌症的方法，包括将c-Met抑制剂和β-连环蛋白抑制剂共同施用于有需要的受试者，包含c-Met抑制剂和β-连环蛋白抑制剂的药物组合物和 包含包含c-Met抑制剂的药物组合物的试剂盒和包含在一起包装的β-连环蛋白抑制剂的药物组合物。
-
19.发明申请公开(公告)号：US20140302039A1
公开(公告)日：2014-10-09
申请号：US14244709
申请日：2014-04-03
Applicant: Samsung Electronics Co., Ltd.
Inventor： Yun Ju JEONG , Kyung Ah Kim , Kyung Eun Kim , Chungho Kim
IPC: A61K39/395
CPC classification number: C07K16/2863 , A61K2039/507 , C07K16/22 , C07K2317/24 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: A method for inhibiting angiogenesis and treating angiogenesis related diseases comprising administering an anti-c-Met antibody or an antigen-binding fragment thereof, and an anti-Ang-2 antibody or an antigen-binding fragment thereof, in combination simultaneously or sequentially; as well as related compositions and methods.
Abstract translation: 一种抑制血管生成和治疗血管发生相关疾病的方法，包括同时或依次给予抗c-Met抗体或其抗原结合片段，以及抗Ang-2抗体或其抗原结合片段; 以及相关的组合物和方法。
-
公开(公告)号：US10188647B2
公开(公告)日：2019-01-29
申请号：US14167711
申请日：2014-01-29
Applicant: Samsung Electronics Co., Ltd.
Inventor： Young Mi Oh , Kyung Ah Kim
IPC: A61K31/49 , A61K31/496 , C07K16/28 , A61K45/06 , A61K31/122 , A61K31/497 , A61K39/395
Abstract: A method of preventing and/or treating a cancer comprising co-administering a p53 activator and a c-Met inhibitor to a patient in need thereof.
-
-
-
-
-
-
-
-
-
Search Results
39
records
(took 0.035 seconds)
